RT info:eu-repo/semantics/article
T1 Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors
A1 González Martínez, Alicia
A1 Guerrero Peral, Angel Luis
A1 Arias Rivas, Susana
A1 Silva, Lorenzo
A1 Sierra, Álvaro
A1 Gago Veiga, Ana Beatriz
A1 García Azorín, David
K1 Migraine
K1 Amitriptyline
K1 COVID-19
K1 Tension-type headache
K1 Long-haulers
K1 32 Ciencias Médicas
AB Background Headache is one of the most frequently reported symptoms in post-COVID patients. The clinical phenotype of COVID-19 headache combines phenotypic features of both tension-type headache (TTH) and migraine. We aimed to assess the efectiveness, side efects and predictors of amitriptyline (AMT) response in a real-world study setting.Methods We performed an observational multicentric study with a retrospective cohort. All consecutive patients with con frmed COVID-19 infection who received AMT for post-COVID headache from March 2020 to May 2021 were included. Response was evaluated by the reduction in the number of headache days per month (HDM) between weeks 8 and 12, compared with the baseline. We explored which variables were associated with a higher probability of response to AMT.Results Forty-eight patients were eligible for the study, 40/48 (83.3%) females, aged 46.85 (SD: 13.59) years. Patients had history of migraine 15/48 (31.3%) or TTH 5/48 (10.4%). The mean reduction of HDM was 9.6 (SD: 10.9; 95% CI 6.5, 12.7) days. Only 2/48 (5%) of patients discontinued AMT due to poor tolerability. History of TTH (10.9, 95% CI 1.3, 20.6) and nausea (−8.5, 95% CI −14.6, −2.5) were associated with AMT response.Conclusions This study provides real-world evidence of the potential beneft of AMT in patients with post-COVID-19 headache, especially in patients with history of TTH and without concomitant nausea.
PB Springer
SN 0340-5354
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/54400
UL https://uvadoc.uva.es/handle/10324/54400
LA eng
NO Journal of Neurology, 2022.
NO Producción Científica
DS UVaDOC
RD 15-jun-2024